Jaume Pons
President and CSO at ALX Oncology
Burlingame, California
Overview
Work Experience
President and CSO
2023 - Current
President and CEO
2015 - 2023
We are a clinical stage company dedicated to developing novel biologics that are both safe and efficacious for use in combination with anticancer antibodies to help the immune system eradicate cancer. More information at: http://alxoncology.com/
President and CEO
2015 - 2023
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Raised $329,200,000.00 from Silicon Valley Bank and Oxford Finance LLC.
Venbio Venture partner
2015
VenBio is a life sciences investment firm that partners with industry leaders to build medicines and technologies.
Pfizer SVP and Rinat CSO
2009 - 2015
CSO (Chief Scientific Officer) of Rinat (acquired by Pfizer) and reporting to Dr. Mikael Dolsten, M.D. President of Pfizer World Research and Development (WRD). I also served as SVP at Pfizer and member of the Pfizer WRD Leadership Team, served as Chief Technology Officer for Pfizer Biotherapeutics, member of Pfizer Senior Leadership Council and Pfizer South San Francisco Site Head.
VP and Rinat CSO
2008 - 2009
Chief Scientific Officer, Rinat
2007 - 2009
I am responsible for Rinat. Rinat is a scientifically independent company within a new Biotherapeutic initiative of Pfizer: The Biotherapeutics and Bioinnovation Centre (BBC). Reporting to Corey Goodman, companies in the BBC keep most of their independence while work closely with Pfizer to expand the biotherapeutics portfolio, the result is an organization that combines Biotech spirit with Pfizer’s Research, Development and Commercial capabilities.
Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.
Raised $32,000,000,000.00 from Starboard Value.
Scientist 2
1999 - 2002
Posdoc (Kirsch lab)
1996 - 1999